Roche’s Phase 3 kidney-drug win sets up a fight with Novartis on September 23, 2026 Accelerated Approved Complement Factor B Epidermal Growth Factor Receptor Fabhalta IgA IGA Glomerulonephritis Ionis Pharmaceuticals Novartis Phase 3 Proteinuria Roche (company) sefaxersen +